SLC5A2 and Stroke: However, another meta-analysis of trials with SGLT-2 inhibitors, this time including studies lasting at least 24 weeks and reporting at least one cardiovascular outcome, did not confirm an increased risk of stroke, thus assuring a reasonable level of cerebrovascular safety with this class of drugs [64].